Patents Examined by Carlos A. Azpuru
  • Patent number: 11324715
    Abstract: The invention relates to bismuth-thiol compounds and pharmaceutical preparations thereof. The invention further relates to methods for treating a topical wound, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a bismuth-thiol compound, wherein the composition is applied to the infection. Methods for treating microbial infections such as diabetic foot infections are also provided.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: May 10, 2022
    Assignee: MICROBION CORPORATION
    Inventor: Brett Hugh James Baker
  • Patent number: 11324863
    Abstract: In some aspects, the present invention provides surgical procedures that comprise applying compositions into and/or onto pelvic tissue to provide support to the pelvic tissue. The injectable hydrogel composition comprises a polysaccharide. In embodiments, the polysaccharide comprises one or more of a glycosaminoglycan, chitosan, hyaluronic acid, dextran, alginic acid and hydroxyethyl starch. In other aspects, the present disclosure pertains to kits that are useful for performing such procedures.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: May 10, 2022
    Assignee: BOSTON SCIENTIFIC SCIMED, INC.
    Inventors: Sandra Nagale, Mark W. Boden, Andrew Dolan
  • Patent number: 11324854
    Abstract: Disclosed is a process for the preparation of hydrogels consisting of crosslinked glycosaminoglycans, which comprises: a) reacting at least one hybrid cooperative complex obtained by heating aqueous solutions of low- and high-molecular-weight glycosaminoglycans at 80-160° C. with a diepoxide as crosslinker in a ratio with the complex ranging between 0.1 and 1 equivalents, preferably between 0.2 and 0.4 equivalents, the concentration by weight of the complex in the solution ranging between 1% and 15%, preferably between 2% and 10%; b) purifying by dialysis, ultrafiltration and diafiltration.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: May 10, 2022
    Assignee: Altergon SA
    Inventors: Nicola Solimando, Maurizio Pagliuca
  • Patent number: 11324760
    Abstract: A solid dispersion of dutasteride for improving the solubility or dissolution rate of poorly soluble dutasteride, a method for preparing the solid dispersion, and a pharmaceutical composition including the solid dispersion are provided. The solid dispersion includes: a coprecipitate including dutasteride and a water-soluble polymeric carrier; and an adsorbent. The dutasteride and the water-soluble polymeric carrier are present in a weight ratio of 1:10-100 in the coprecipitate.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: May 10, 2022
    Assignee: KOREA PRIME PHARM CO., LTD.
    Inventors: Dae Ik Kim, Woo Cheoul Shin
  • Patent number: 11318156
    Abstract: The present invention relates to an injectable implant comprising an effective amount of a macrocyclic lactone, or a salt thereof, and a bioresorbable polymer, and its use in preventing and/or treating parasites infestations in non human mammals, especially pets.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: May 3, 2022
    Assignee: CEVA SANTE ANIMALE
    Inventors: Florence Guimberteau, Patrick Forget
  • Patent number: 11318213
    Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: May 3, 2022
    Assignee: HDT BIO CORP.
    Inventors: Amit Khandhar, Steven Reed, Malcolm Duthie, Jesse Erasmus, Darrick Carter, Bryan J. Berube
  • Patent number: 11311492
    Abstract: A nanomedicine for the treatment of obesity comprising either noble metal nanoparticles having surface ligands comprising a mixture comprising (+)-catechin (2R,3S) and gingerol or particles of a carbon nanomaterial having an adsorbed mixture comprising (+)-catechin (2R,3S) and gingerol. Also provided are a method for making the noble metal nanomedicine and the carbon nanomedicine. The nanomedicine is used in a method of treating obesity.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: April 26, 2022
    Assignee: King Abdulaziz University
    Inventors: Imran Kazmi, Syed Sarim Imam, Muhammad Afzal, Muhammad Shahid Nadeem, Fahad A. Al-Abbasi, Firoz Anwar
  • Patent number: 11311630
    Abstract: Embodiments of the present disclosure provide for magnetic particle conjugates, methods of making the magnetic particle conjugates, methods of using magnetic particle conjugates, micelles (also referred to as a “magnetic composite nanocarrier” (MCNC)), methods of making micelles, methods of using micelles, and the like.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: April 26, 2022
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Carlos Rinaldi, Sun Hao, Brent S. Sumerlin
  • Patent number: 11305039
    Abstract: The present invention relates generally to shape memory polymer devices that are porous. The porosity of the device may generate advantageous neovascularization, decrease inflammation, and decrease fibrosis. The device may include a surface having a pore size of 500-750 microns and a pore spacing of 220-250 microns.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: April 19, 2022
    Assignees: Vanderbilt University, Venostent, Inc.
    Inventor: Timothy C. Boire
  • Patent number: 11304999
    Abstract: Composition are described, which are dried under reduced pressure from a liquid mixture comprising an adjuvant comprising a saponin (e.g., such as QS21) in a liposomal formulation wherein the liposomes contain a neutral lipid (e.g., such as a phosphatidylcholine) and a sterol (e.g., such as cholesterol), and, a cryoprotectant that is an amorphous sugar. The adjuvant may further comprises a TLR-4 agonist. The compositions may further comprising an antigen, such as an antigen derived from Plasmodium falciparum, Mycobacterium tuberculosis, HIV, Moraxella, ntHi or Varicella Zoster Virus. The cryoprotectant is an amorphous sugar or mixture of amorphous sugars, and preferably is a combination of at least two cryoprotectants selected from sucrose, trehalose and dextran. The compositions may further comprise a buffer and/or a surfactant.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: April 19, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Dominique Ingrid Lemoine, Nicolas Moniotte
  • Patent number: 11304974
    Abstract: A composition including metallic silver nanoparticles is supported on a carrier, wherein the carrier is in the form of particles. The carrier is selected from an inert carrier or an antibiotic. The composition further includes at least one antibiotic in the case the carrier is an inert carrier. A related nanosystem includes a composition having metallic silver nanoparticles or a mixture of silver nanoparticles and at least one antibiotic for use in the treatment of an infection caused by at least one strain of bacteria resistant to at least one antibiotic. Pharmaceutical compositions and methods for the preparation of these compositions and nanosystems are also used for the treatment of bacterial infections.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: April 19, 2022
    Assignee: LABORATORIOS ENOSAN, S.L.
    Inventor: Luis Jesús Lostao Camón
  • Patent number: 11285102
    Abstract: An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: March 29, 2022
    Assignee: Clexio Biosciences Ltd.
    Inventors: Avshalom Ben Menachem, Ilan Zalit
  • Patent number: 11285109
    Abstract: The present application provides a microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) or polylactide (PLA) as a main component, in which a biologically active substance is uniformly dispersed, wherein an average volume-based particle diameter of the microsphere is 1 ?m or more and 150 ?m or less, and a variation coefficient of area ratios in six regions is 0.35 or less, wherein the area ratios in six regions are calculated by (s/A)×100 (%) wherein the six regions are prepared by preparing a cross section observation sample obtained by cutting the microsphere; observing the cross section observation sample with an electron microscope at a magnification capable of confirming the biologically active substance in the microsphere or a higher magnification; and dividing the electron microscope observation image into six regions; and A is an area of a respective divided region, and s is a sum of cross section areas of the biologically active substance included in the respective divided region.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: March 29, 2022
    Assignee: M. TECHNIQUE CO., LTD.
    Inventors: Masakazu Enomura, Kaeko Araki
  • Patent number: 11286171
    Abstract: The invention is directed to a composition of metal particles and methods of manufacturing and using the composition in the treatment of microbial infections and cancer. The particles can be nanoparticles having coupled thereto at least one of a surfactant, an antibiotic, and a drug. The particles of the invention achieve enhanced stability, enhanced cytotoxicity, and enhanced antimicrobial activity through novel combinations of metals, surfactants, antibiotics, and drugs.
    Type: Grant
    Filed: October 31, 2020
    Date of Patent: March 29, 2022
    Inventors: Regina Vertelova, Nikolai Tankovich
  • Patent number: 11266617
    Abstract: The present invention provides compositions comprising ?-hydroxybutyrate, cyclic or linear ?-hydroxybutyrate oligomers, and/or ?-hydroxybutyrate ester derivatives, or pharmaceutically-acceptable salts thereof. In various embodiments, the compositions are encapsulated by nanoparticles, such as nanoparticles comprising, e.g., poly(lactic-co-glycolic acid). In additional embodiments, the invention provides methods of using such compositions to induce intestinal stem cell regeneration and/or treat radiation-induced intestinal damage in a subject.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 8, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Omer Yilmaz, Chia-Wei Cheng, George Eng, Fang Wang
  • Patent number: 11266741
    Abstract: There are provided PVP-PLA block copolymers as defined in Formula (I): I wherein, x is an initiator alcohol having a boiling point greater than 145° C., n is, on average, from 20 and 40, and m is, on average, from 10 and 40, wherein the block copolymers have a number average molecular weight (Mn) of at least 3000 Da. Polymers demonstrating flexibility in formulating multiple low-solubility active pharmaceutical ingredients (APIs) are described. Liquid and dry pharmaceutical formulations comprising an API are described, along with delivery methods, uses, and kits. APIs may include, e.g. flurbiprofen, celecoxib, acetaminophen, or propofol. Also provided is a method of synthesizing the PVP-PLA block copolymers by (i) initiating polymerization of D,L-Lactide from the initiator alcohol x to form poly(lactic acid), adding a xanthate to form a PLA macroinitiator, and polymerizing NVP onto the PLA macroinitiator, by controlled polymerization, to form the block copolymer compound of Formula (I).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 8, 2022
    Assignee: Altus Formulation Inc.
    Inventors: Damon Smith, Wilms Baille, Piotr Kujawa
  • Patent number: 11241426
    Abstract: Provided is an aqueous composition for ophthalmic or nasal administration comprising levocetirizine or its salt. In one embodiment, the composition comprises levocetirizine or its salt at a levocetirizine concentration of 0.05-0.5% (w/v). The composition may further comprise a surface active agent and/or an organic acid salt.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: February 8, 2022
    Assignee: Nitto Medic Co., Ltd.
    Inventor: Mineo Onuki
  • Patent number: 11241378
    Abstract: A pharmaceutical composition for topical administration and a preparation method therefor are described. In particular, a pharmaceutical composition comprising (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxamide, or a pharmaceutically acceptable salt thereof, and diethylene glycol monoethyl ether is described.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: February 8, 2022
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Honglei Xi, Qiudong Jiang
  • Patent number: 11241538
    Abstract: Devices that are placed within fluid filled organs, such as the bladder, which reduce the risk of bacterial infections using a combination of active agents and mechanical disruption of bacteria.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: February 8, 2022
    Assignee: Watershed Medical, Inc.
    Inventors: Christopher Ralph Kinsella, Jr., Clay Nolan, Rush Bartlett
  • Patent number: 11234435
    Abstract: A composition that can solvate biofilms and disrupt bacterial cell walls acts to both kill the bacteria by cell lysis and remove the biofilm. This solvent-containing composition is effective against a broad spectrum of microbes and can be used on a variety of surfaces, both living and inanimate. The polarity of the solvent component of the composition is lower than that of pure water so that the composition exhibits increased efficacy in solvating the macromolecular matrix of a biofilm and in penetrating bacterial cell walls.
    Type: Grant
    Filed: November 16, 2019
    Date of Patent: February 1, 2022
    Assignee: Next Science IP Holdings Pty Ltd
    Inventor: Matthew F. Myntti